Olink Proteomics’ Post

Powerful, specific and robust - and also a scalable technology :-)

Interested in learning more about how to use Olink's protein assays for your studies? talk with the team at #DLS today to learn more, scope out projects, and see how our multi-omic capabilities (NGS, 10x, IHC, etc) can help maximize your sample use and data sets. #Olink #multiomics #clinicalstudies #preclinical

Clinical proteomics, along with metabolomics, is the key for understanding complex pathological processes. It reveals the real mechanism of the disease and explains the observed changes in the genome. Bruker delivers the tools for unveiling and understanding the processes.

Single-Cell Proteomics (SCP): Unprecedented Sensitivity, Throughput, and PTM Detection in a Nearly Lossless Workflow 🔻 Unparalleled Sensitivity: Advanced SCP workflow by Ye, Sabatier, and co-authors, doubles protein identification, pushing the boundaries from 2000 to over 5000 proteins in individual cells 🔻 Enhanced Throughput: 80 label-free SCP samples per day 🔻 Direct PTM Detection: Eliminated enrichment Read more: https://lnkd.in/g96Mh9uW #Proteomics #MassSpectrometry #SingleCellAnalysis

Free webinar: Listen to Chiara Guerrera, clinical proteomics expert at Necker Hospital in Paris, as she talks about optimized analysis of neat plasma along with an enrichment analysis of functionalized nanoparticles and in-depth urine analysis with concrete examples. Register here: https://lnkd.in/ehaNHu9u #proteomics #clinicalproteomics #plasmaproteomics #plasma #massspectrometry

Source: Journal of proteomics Glypican-1 may be a plasma biomarker for predicting the rupture of small intracranial aneurysms. A study found that the plasma concentration of GPC1 was significantly higher in patients with ruptured intracranial aneurysms compared to those with unruptured aneurysms. Logistic regression analysis identified GPC1 as an independent risk factor for predicting aneurysm rupture. The study suggests that GPC1 could serve as an early warning biomarker for predicting the rupture of small intracranial aneurysms.

Until very recently, blood plasma posed significant challenges for MS proteomics due to its wide dynamic range of protein abundances. Available solutions, such as protein depletion, fell short in providing the necessary depth and throughput required for population-wide studies. However, thanks to the (re-)discovery (credits to Prof. em. Righetti) of surface-interaction-based enrichment methods, we can now achieve a level of depth and throughput that was previously attainable only for simpler sample types like cell cultures. This marks just the beginning of an exciting innovation curve. Yet, our pursuit extends beyond mere record numbers. We must transform the allegorical notion of plasma as a “window to the body” into practical reality. By harnessing the wealth of protein data available, including protein modifications and protein-protein interactions, we can unlock deeper insights. Revolutions in science have often been preceded by revolutions in measurement (Sinan Aral). While one part of this journey is far advanced, the other lies still ahead of us.

As groundbreaking drugs that eliminate disease-causing proteins by recruiting cellular machinery for degradation, targeted protein degraders (TPD) have enormous potential in cancer and other conditions that have historically been challenging to target with conventional small molecules. Mass spectrometry-based proteomics is crucial for TPD research and drug development, and we're here to help, with efficient and reproducible proteomics sample preparation solutions to ensure successful outcomes. Explore these outstanding publications to understand how iST-based proteomics sample preparation can be applied in TPD research. https://ow.ly/17MS50QKFh6 #MassSpec #LCMS #samplepreparation #oncology #TPD #proteindegradation #drugdevelopment #PreOmics

Achieve the full potential of your research with Biogenity's comprehensive multiomics analysis - spanning Transcriptomics, Proteomics, Lipidomic, and Metabolomics. 🔍 Why rely on a single omics approach when multiomics offers a holistic view, accelerating discoveries in diagnostics, treatment, and personalized medicine? 🔬 From Proteomics to Metabolomics and specialized areas like Phosphoproteomics and miRNA, we're here to guide you through every step. Set up an online meeting with us today to explore how Biogenity can empower your research. #Biogenity #Multiomics #Proteomics #Metabolomics #Transcriptomics #Lipidomics 🔗

Proteomics can help us gain a better understanding of disease mechanisms, drug targets, and biomarker diversity. Discover the Photoreactor m2’s role in this important research field: https://ow.ly/oFu250Qy7xU #Proteomics #Photocatalysis #Biochemistry